Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urtica Dioica Cataplasm for Osgood-Schlatter Disease
NCT07096037Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Sep 2025
01
Overview
Randomised, double-blind trial in Osgood-Schlatter disease (OSD) (3 arms). Primary endpoint: Pain intensity at 6 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
Osgood-Schlatter disease (OSD)
Beyond the preview
Go deeper on NCT07096037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096037.